PATENT CLAIM ANALYSIS

Application Number: 15761995
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-09
Patent Classification: ["514", "210180"]

Abstract:
Provided herein are methods for treating, preventing, or ameliorating one or more symptoms of a condition, disorder, or disease mediated by a lipid kinase or a protein kinase with benzimidazoles, for example, of Formula I or II, and pharmaceutical compositions thereof. Also provided herein are benzimidazoles, and pharmaceutical compositions thereof; and methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.

Claim (Index 161):
A compound of Formula IX-A: or a single enantiomer, a racemic mixture, a mixture of diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein:\n R 1  is \u2014C(O)CR 1e \u2550CR 1f CR 1g , \n \u2014N 1a C(O)CR 1e \u2550CR 1f CR 1g , \u2014S(O)CR 1e \u2550CR 1f CR 1g , \u2014S(O 2 )CR 1e \u2550CR 1f CR 1g , \u2014NR 1a S(O)CR 1e \u2550CR 1f CR 1g , \u2014NR 1a S(O 2 )CR 1e \u2550CR 1f CR 1g , or R 2  is C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl; R 4  and R 5  are each independently (a) hydrogen, cyano, halo, or nitro; (b) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl; or (c) \u2014C(O)R 1a , \u2014C(O)OR 1a , \u2014C(O)NR 1b R 1c , \u2014C(NR a )NR 1b R 1c , \u2014OR 1a , \u2014OC(O)R 1a , \u2014OC(O)OR 1a , \u2014OC(O)NR 1b R 1c , \u2014OC(\u2550NR 1a )NR 1b R 1c , \u2014OS(O)R 1a , \u2014OS(O) 2 R 1a , \u2014OS(O)NR 1b R 1c , \u2014OS(O) 2 NR 1b R 1c , \u2014NR 1b R 1c , \u2014NR 1a C(O)R 1d , \u2014NR 1a C(O)OR 1d , \u2014NR 1a C(O)NR 1b R 1c , \u2014NR 1a C(\u2550NR 1d )NR 1b R 1c , \u2014NR 1a S(O)R 1d , \u2014NR 1a S(O) 2 R 1d , \u2014NR 1a S(O)NR 1b R 1c , \u2014NR 1a S(O) 2 NR 1b R 1c , \u2014SR 1a , \u2014S(O)R 1a , \u2014S(O) 2 R 1a , \u2014S(O)NR 1b R 1c , or \u2014S(O) 2 NR 1b R 1c ; R 6a  is (a) hydrogen, cyano, halo, or nitro; (b) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl; or (c) \u2014C(O)R 1a , \u2014C(O)OR 1a , \u2014C(O)NR 1b R 1c , \u2014C(NR 1a )NR 1b R 1c , \u2014OR 1a , \u2014OC(O)R 1a , \u2014OC(O)OR 1a , \u2014OC(O)NR 1b R 1c , \u2014OC(\u2550NR 1a )NR 1b R 1c , \u2014OS(O)R 1a , \u2014OS(O) 2 R 1a , \u2014OS(O)NR 1b R 1c , \u2014OS(O) 2 NR 1b R 1c , \u2014NR 1b R 1c , \u2014NR 1a C(O)R 1d , \u2014NR 1a C(O)OR 1d , \u2014NR 1a C(O)NR 1b R 1c , \u2014NR 1a C(\u2550NR 1d )NR 1b R 1c , \u2014NR 1a S(O)R 1d , \u2014NR 1a S(O) 2 R 1d , \u2014NR 1a S(O)NR 1b R 1c , \u2014NR 1a S(O) 2 NR 1b R 1c , \u2014SR 1a , \u2014S(O)R 1a , \u2014S(O) 2 R 1a , \u2014S(O)NR 1b R 1c , or \u2014S(O) 2 NR 1b R 1c ; each R 1a , R 1b , R 1c , and R 1d  is independently hydrogen, C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-7  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl; or R 1a  and R 1c  together with the C and N atoms to which they are attached form heterocyclyl; or R 1b  and R 1c  together with the N atom to which they are attached form heterocyclyl; and each R 1e , R 1f , and R 1g  is independently hydrogen, halo, C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-7  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q, where each Q is independently selected from (a) oxo, cyano, halo, and nitro; (b) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-7  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q a ; and (c) \u2014C(O)R a , \u2014C(O)OR a , \u2014C(O)NR b R c , \u2014C(NR a )NR b R c , \u2014OR a , \u2014OC(O)R a , \u2014OC(O)OR a , \u2014OC(O)NR b R c , \u2014OC(\u2550NR a )NR b R c , \u2014OP(O)(OR a ) 2 , \u2014OS(O)R a , \u2014OS(O) 2 R a , \u2014OS(O)NR 1b R 1c , \u2014OS(O) 2 NR b R c , \u2014NR b R c , \u2014NR a C(O)R d , \u2014NR a C(O)OR d , \u2014NR a C(O)NR b R c , \u2014NR a C(\u2550NR d )NR b R c , \u2014NR a S(O)R d , \u2014NR a S(O) 2 R d , \u2014NR a S(O)NR b R c , \u2014NR a S(O) 2 NR b R c , \u2014SR a , \u2014S(O)R a , \u2014S(O) 2 R a , \u2014S(O)NR b R c , and \u2014S(O) 2 NR b R c , wherein each R a , R b , R c , and R d  is independently (i) hydrogen; (ii) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-7  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q a ; or (iii) R b  and R c  together with the N atom to which they are attached form heterocyclyl, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q a ; wherein each Q a  is independently selected from the group consisting of (a) oxo, cyano, halo, and nitro; (b) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-7  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, and heterocyclyl; and (c) \u2014C(O)R f , \u2014C(O)OR f , \u2014C(O)NR g R h , \u2014C(NR f )NR g R h , \u2014OR f , \u2014OC(O)R f , \u2014OC(O)OR f , \u2014OC(O)NR g R h , \u2014OC(\u2550NR f )NR g R h , \u2014OP(O)(OR f ) 2 , \u2014OS(O)R f , \u2014OS(O) 2 R f , \u2014OS(O)NR g R h , \u2014OS(O) 2 NR g R h , \u2014NR g R h , \u2014NR f C(O)R k , \u2014NR f C(O)OR k , \u2014NR f C(O)NR g R h , \u2014NR f C(\u2550NR k )NR g R h , \u2014NR f S(O)R k , \u2014NR f S(O) 2 R k , \u2014NR f S(O)NR g R h , \u2014NR f S(O) 2 NR g R h , \u2014SR f , \u2014S(O)R f , \u2014S(O) 2 R f , \u2014S(O)NR g R h , and \u2014S(O) 2 NR g R h ; wherein each R f , R g , R h , and R k  is independently (i) hydrogen; (ii) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-7  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl; or (iii) R g  and R h  together with the N atom to which they are attached form heterocyclyl.

Metadata:
- Claim Count in Document: 86.0
- Percentile: 96.0
- Lexical Diversity: 2.025
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15127000', '16005490', '14489231', '13431716', '13830712']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8313758422260176
- 35 USC 102 Novelty (BERT): 0.5703695093293217
- Combined Prediction Score: 0.805275208936348
- Mean Citation Score: 435.272624
- Max Citation Score: 474.12836
- Similarity Product: 361.555452919054

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test